PTC Therapeutics (FRA:BH3) FFO


FRA:BH3 PTC Therapeutics Inc FRA:BH3
51 GF Score
Price €72.26
GF Value €30.17
! 9 Warning Signs
View Full Analysis

What is PTC Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

FRA:BH3
51GF Score
PTC Therapeutics Inc FRA:BH3
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €72.26 is trading 139.5% above its estimated GF Value™ of €30.17.

Key valuation signals for FRA:BH3:

  • FFO:
  • GF Value™: €30.17 vs. price of €72.26 (139.5% above fair value)
  • GF Score™: 51/100 with 9 warning signs

No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PTC Therapeutics Business Description

Other Exchanges PTCT:USABH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
51GF Score

Get the complete analysis for FRA:BH3

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€72.26
Price
€30.17
GF Value